Blog

Emre Yekedüz: LEANOX Trial – Lean Body Mass–Based Oxaliplatin Dosing in Stage III Colon Cancer

Emre Yekedüz/X

Jun 23, 2025, 07:31

Emre Yekedüz: LEANOX Trial – Lean Body Mass–Based Oxaliplatin Dosing in Stage III Colon Cancer

Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, shared a post on X:

“Lean body mass–based oxaliplatin dosing reduces peripheral neuropathy in stage III colon cancer without compromising survival!

Lower rates of grade ≥2 oxaliplatin-induced peripheral neuropathy.

Better quality of life.

No impact on relapse-free survival or overall survival.

Proof-of-concept randomized trial.”

Title: Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial

Authors: Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou, Hervé Perrier, Faiza Khemissa Akouz, Romain Desgrippes, Marie-Pierre Galais, Chloé Janiszewski, Thibault Mazard, Yves Rinaldi, Côme Lepage, Raphael Tetreau, Pierre Senesse

Read The Full Article at Journal of Clinical Oncology.

Emre Yekedüz: LEANOX Trial - Lean Body Mass–Based Oxaliplatin Dosing in Stage III Colon Cancer

More posts featuring Colon Cancer.

Chloé Janiszewski Colon cancer Côme Lepage Emre Yekedüz Eric Assenat Faiza Khemissa Akouz Hervé Perrier Marie-Pierre Galais Meher Ben Abdelghani Pierre Senesse Raphael Tetreau Romain Desgrippes Sophie Gourgou Thibault Mazard Yves Rinaldi

BEATcc Trial at ESMOGynaec25: Atezolizumab Benefits Cervical Cancer Patients Regardless of PD-L1 Status

15 Posts Not to Miss from EACR 2025

ASCO 2025 RCC Advances: Expert Insights by Ilya Tsimafeyeu

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself